BioVie Inc. Announces Phase 2 SUNRISE‑PD Results for Bezisterim

What Happened
BioVie Inc. (BIVI) announced clinical results from its Phase 2 SUNRISE‑PD trial evaluating bezisterim in early‑stage Parkinson’s disease. The company issued a press release on August 6, 2026, and filed a Form 8‑K (Item 7.01) to disclose the information under Regulation FD; the press release is attached as Exhibit 99.1 to the filing.

Key Details

• Date of disclosure: August 6, 2026 (press release and Form 8‑K filed).
• Trial/drug: Phase 2 SUNRISE‑PD trial evaluating bezisterim in early‑stage Parkinson’s disease.
• Filing type: Item 7.01 Regulation FD disclosure; press release incorporated by reference as Exhibit 99.1.
• The Form 8‑K itself points investors to the attached press release for the full results and details.

Why It Matters
This filing communicates new clinical data about BioVie’s lead candidate, bezisterim—information that can affect the company’s development timeline, regulatory planning, and investor evaluation of its Parkinson’s program. Retail investors should read the attached press release (Exhibit 99.1) for the specific trial outcomes, any stated next steps, and management commentary.